2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Refractory Ewing Sarcoma: new trials by email Literature Review of Refractory Ewing Sarcoma trials Research Report on Refractory Ewing Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma Linsitinib - Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma | Phase 2 | Completed | University of Oxford | 16 | 2014-03-01 | 2019-06-03 |
Sarcoma, Ewing (2) · Ependymoma (1) · Familial ependymoma (1) · Glioma (1) · Hepatoblastoma (1) · Histiocytosis, Langerhans-Cell (1) · Lymphoma, Non-Hodgkin (1) · Medulloblastoma (1) · Neuroblastoma (1) · Neuroectodermal Tumors, Primitive, Peripheral (1) · Osteosarcoma (1) · Rhabdoid Tumor (1) · Rhabdomyosarcoma (1) · Sarcoma (1) · Wilms Tumor (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Bone Tissue (2) · Neoplasms, Connective Tissue (2) · Neoplasms, Connective and Soft Tissue (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genetic Diseases, Inborn (1) · Hemic and Lymphatic Diseases (1) · Histiocytosis (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Kidney Diseases (1) · Kidney Neoplasms (1)
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (1) · palbociclib (1)
National Cancer Institute (NCI) (1) · University of Oxford (1)
France (1) · Germany (1) · Italy (1) · Netherlands (1) · Puerto Rico (1) · United Kingdom (1) · United States (1)
Andrew B Hassan, BMBCh FRCP (1) · Rajen Mody (1)
U10CA180886 (1)